Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1992 May;45(5):427–430. doi: 10.1136/jcp.45.5.427

Development of acute leukaemia after idiopathic myelofibrosis.

J M Hernández 1, J F San Miguel 1, M González 1, A Orfao 1, M C Cañizo 1, C Bascones 1, J Hernández 1, A López Borrasca 1
PMCID: PMC495307  PMID: 1597522

Abstract

AIMS: To determine the characteristics of blastic transformation of idiopathic myelofibrosis. METHODS: The clinical and haematological features, as well as the morphological characteristics of blast cells, were analysed in nine adults with blast transformation. RESULTS: Most of the patients were male and had enlarged spleens and livers. Five of the patients had normal platelet counts, while all had pronounced anaemia and a moderate degree of leucocytosis. The duration of the acute phase was usually short: 16 (SD 8) weeks. Most myeloid cell lineages--granulocytic, monocytic, and megakaryocytic--were similarly distributed. One patient also had a hybrid (lymphoid-myeloid) phenotype. The morphological assessment of blast cells agreed with immunophenotyping in five out of the nine cases. The onset of the blastic phase was not related to previous treatment. CONCLUSIONS: A pluripotential stem cell with preferential myeloid commitment would be the target cell of blast transformation in idiopathic myelofibrosis. Our immunophenotypic data do not support the concept of a preferential association between megakaryocytic lineage and the acute transformation of idiopathic myelofibrosis. The absence of previous treatment in some cases suggests that this kind of evolution is part of the natural history of idiopathic myelofibrosis.

Full text

PDF
427

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bain B. J., Catovsky D., O'Brien M., Prentice H. G., Lawlor E., Kumaran T. O., McCann S. R., Matutes E., Galton D. A. Megakaryoblastic leukemia presenting as acute myelofibrosis -- a study of four cases with the platelet-peroxidase reaction. Blood. 1981 Aug;58(2):206–213. [PubMed] [Google Scholar]
  2. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Sep;103(3):460–462. doi: 10.7326/0003-4819-103-3-460. [DOI] [PubMed] [Google Scholar]
  3. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  4. Bettelheim P., Lutz D., Majdic O., Paietta E., Haas O., Linkesch W., Neumann E., Lechner K., Knapp W. Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol. 1985 Mar;59(3):395–409. doi: 10.1111/j.1365-2141.1985.tb07326.x. [DOI] [PubMed] [Google Scholar]
  5. Brandt L., Mitelman F., Panani A. Cytogenetic differences between bone marrow and spleen in a case of agnogenic myeloid metaplasia developing blast crisis. Scand J Haematol. 1975 Oct;15(3):187–191. doi: 10.1111/j.1600-0609.1975.tb01073.x. [DOI] [PubMed] [Google Scholar]
  6. Canellos G. P. Clinical characteristics of the blast phase of chronic granulocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr;4(2):359–367. [PubMed] [Google Scholar]
  7. Castro-Malaspina H., Rabellino E. M., Yen A., Nachman R. L., Moore M. A. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981 Apr;57(4):781–787. [PubMed] [Google Scholar]
  8. Choate J. J., Domenico D. R., McGraw T. P., Fareed J., Molnar Z., Schumacher H. R. Diagnosis of acute megakaryoblastic leukemia by flow cytometry and immunoalkaline phosphatase techniques. Utilization of new monoclonal antibodies. Am J Clin Pathol. 1988 Feb;89(2):247–253. doi: 10.1093/ajcp/89.2.247. [DOI] [PubMed] [Google Scholar]
  9. Garcia S., Miguel A., Miguel A., Linares M., Navarro M., Colomina P. Idiopathic myelofibrosis terminating in erythroleukemia. Am J Hematol. 1989 Sep;32(1):70–71. doi: 10.1002/ajh.2830320114. [DOI] [PubMed] [Google Scholar]
  10. Griffin J. D., Todd R. F., 3rd, Ritz J., Nadler L. M., Canellos G. P., Rosenthal D., Gallivan M., Beveridge R. P., Weinstein H., Karp D. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan;61(1):85–91. [PubMed] [Google Scholar]
  11. Groopman J. E. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med. 1980 Jun;92(6):857–858. doi: 10.7326/0003-4819-92-6-857. [DOI] [PubMed] [Google Scholar]
  12. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990 Aug;34(4):291–300. doi: 10.1002/ajh.2830340411. [DOI] [PubMed] [Google Scholar]
  13. Jacobs P., le Roux I., Jacobs L. Megakaryoblastic transformation in myeloproliferative disorders. Cancer. 1984 Jul 15;54(2):297–302. doi: 10.1002/1097-0142(19840715)54:2<297::aid-cncr2820540219>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  14. Janossy G., Woodruff R. K., Pippard M. J., Prentice G., Hoffbrand A. V., Paxton A., Lister T. A., Bunch C., Greaves M. F. Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia. Cancer. 1979 Feb;43(2):426–434. doi: 10.1002/1097-0142(197902)43:2<426::aid-cncr2820430204>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  15. Kantarjian H. M., Keating M. J., Talpaz M., Walters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987 Sep;83(3):445–454. doi: 10.1016/0002-9343(87)90754-6. [DOI] [PubMed] [Google Scholar]
  16. LEWIS S. M., SZUR L. MALIGNANT MYELOSCLEROSIS. Br Med J. 1963 Aug 24;2(5355):472–477. doi: 10.1136/bmj.2.5355.468-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Manoharan A. Annotation. Myelofibrosis: prognostic factors and treatment. Br J Haematol. 1988 Jul;69(3):295–298. doi: 10.1111/j.1365-2141.1988.tb02365.x. [DOI] [PubMed] [Google Scholar]
  18. Marcus R. E., Hibbin J. A., Matutes E., Whittle N., Waterfield M. D., Goldman J. M. Megakaryoblastic transformation of myelofibrosis with expression of the c-sis oncogene. Scand J Haematol. 1986 Feb;36(2):186–193. doi: 10.1111/j.1600-0609.1986.tb00826.x. [DOI] [PubMed] [Google Scholar]
  19. Pereira A., Cervantes F., Montserrat E., Rozman C. Mielofibrosis primaria: descripción de una serie de 53 pacientes. Med Clin (Barc) 1989 Apr 15;92(14):521–525. [PubMed] [Google Scholar]
  20. Polliack A., Prokocimer M., Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol. 1980;9(2):211–220. doi: 10.1002/ajh.2830090209. [DOI] [PubMed] [Google Scholar]
  21. Rosenthal D. S., Moloney W. C. Myeloid metaplasia: a study of 98 cases. Postgrad Med. 1969 Mar;45(3):136–142. doi: 10.1080/00325481.1969.11697057. [DOI] [PubMed] [Google Scholar]
  22. San Miguel J. F., Gonzalez M., Cañizo M. C., Anta J. P., Zola H., Lopez Borrasca A. Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. Br J Haematol. 1986 Nov;64(3):547–560. doi: 10.1111/j.1365-2141.1986.tb02211.x. [DOI] [PubMed] [Google Scholar]
  23. San Miguel J. F., Gonzalez M., Cañizo M. C., Ojeda E., Orfao A., Caballero M. D., Moro M. J., Fisac P., Lopez Borrasca A. Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics. Blood. 1988 Aug;72(2):402–407. [PubMed] [Google Scholar]
  24. San Miguel J. F., Hernández J. M., González-Sarmiento R., González M., Sánchez I., Orfao A., Cañizo M. C., López Borrasca A. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood. 1991 Aug 1;78(3):768–774. [PubMed] [Google Scholar]
  25. San Miguel J. F., Ojeda E., Gonzalez M., Orfao A., Cañizo M. C., Sanchez J., Lopez-Borrasca A. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia. 1989 Feb;3(2):108–111. [PubMed] [Google Scholar]
  26. San Miguel J. F., Tavares de Castro J., Matutes E., Rodriguez B., Polli N., Zola H., McMichael A. J., Bollum F. J., Thompson D. S., Goldman J. M. Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. II. Studies with monoclonal antibodies and terminal transferase. Br J Haematol. 1985 Feb;59(2):297–309. doi: 10.1111/j.1365-2141.1985.tb02995.x. [DOI] [PubMed] [Google Scholar]
  27. Silverstein M. N., Brown A. L., Jr, Linman J. W. Idiopathic myeloid metaplasia. Its evolution into acute leukemia. Arch Intern Med. 1973 Nov;132(5):709–712. doi: 10.1001/archinte.132.5.709. [DOI] [PubMed] [Google Scholar]
  28. Varki A., Lottenberg R., Griffith R., Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983 Nov;62(6):353–371. [PubMed] [Google Scholar]
  29. Ward H. P., Block M. H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971 Sep;50(5):357–420. doi: 10.1097/00005792-197109000-00001. [DOI] [PubMed] [Google Scholar]
  30. den Ottolander G. J., te Velde J., Brederoo P., Geraedts J. P., Slee P. H., Willemze R., Zwaan F. E., Haak H. L., Muller H. P., Bieger R. Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases. Br J Haematol. 1979 May;42(1):9–20. doi: 10.1111/j.1365-2141.1979.tb03693.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES